

WHO GUIDELINE ON

Syphilis screening and treatment for pregnant women



WHO GUIDELINE ON

Syphilis screening and treatment for pregnant women



World Health
Organization

WHO guideline on syphilis screening and treatment for pregnant women

ISBN 978-92-4-155009-3

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO guideline on syphilis screening and treatment for pregnant women. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Geneva, Switzerland

CONTENTS

Acknowledgements	iii
Abbreviations and acronyms	iv
Executive summary	1
Rationale for the guidelines	2
Objectives	2
Methods	2
Recommendations	3
Overview of the guidelines for the prevention, treatment and management of STIs	6
STI epidemiology and burden	6
Why new guidelines for the prevention, treatment and management of STIs?	6
Approach to the revision of STI guidelines	7
References	9
1. Introduction	10
1.1 Epidemiology and burden of disease	10
1.2 Laboratory diagnosis and screening	10
1.3 Rationale for new recommendations	12
1.4 Objectives	12
1.5 Target audience	12
1.6 Structure of the guideline	12
2. Methods	13
2.1 Guideline Development Group (GDG)	13
2.2 Questions and outcomes	13
2.3 Reviews of the evidence	13
2.4 Making recommendations	14
2.5 Management of conflicts of interest	15
3. Dissemination and updating the guideline	16
3.1 Dissemination	16
3.2 Updating the STI guidelines and user feedback	16
4. Recommendations on syphilis screening and treatment for pregnant women	17
4.1 Recommendation on syphilis screening for pregnant women	17
4.2 Recommendations on syphilis screening and treatment strategies for pregnant women	18
4.3 Recommendations on syphilis treatment for pregnant women	20
5. Implementation considerations	21
5.1 Adaptation, implementation and monitoring	21
5.2 Consideration on the implementation of antenatal syphilis screening and treatment	21
5.3 Screening and treatment strategies and flowcharts	23
5.4 Interpretation of syphilis test results	25
5.5 Laboratory procedures and quality assurance	26

CONTENTS (CONTINUED)

6. Research implications	27
References	28
Annex A: STI guideline development teams	29
WHO STI Steering Committee	29
Methodologist	30
Systematic Review Team: McMaster University	30
STI Guideline Development Group	31
STI Guideline Development Group: Working group for syphilis	35
STI External Review Group: Working group for syphilis	35
Annex B: Detailed methods for guidelines development	38
Questions and outcomes	38
Priority questions and outcomes on syphilis screening and treatment for pregnant women	39
Review of the evidence	40
Applying the GRADE approach to making the recommendations	43
Annex C: Lists of references for reviewed evidence	44
References for screening versus no screening	44
References for different screening strategies	45

Web annexes available at:

www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/

Web annex D: Evidence tables and evidence-to-decision frameworks

Web annex E: Summary of the declarations of interest and management of conflicts of interest

ACKNOWLEDGEMENTS

The Department of Reproductive Health and Research at the World Health Organization (WHO) would like to thank the members of the STI Guideline Development Group for their consistent availability and commitment to making these guidelines possible. The Department is also grateful to the STI External Review Group for peer reviewing these guidelines, and appreciates the contribution of the WHO Steering Committee. The names of the members of each group are listed below, with full details provided in Annex A.

Special thanks to Dr Nancy Santesso, the guideline methodologist who also led the systematic review process, for her hard work and firm commitment of the guideline development process. We also thank the members of the Systematic Review Team from McMaster University.

We appreciate the overall support of the WHO Guideline Review Committee Secretariat during the guideline development process, with grateful thanks to Dr Susan Norris.

We thank Theresa Ryle for the administrative support, and 400 Communication for assistance with the guideline design and layout. This guideline document was edited by Ms Jane Patten, of Green Ink, United Kingdom.

Dr Teodora Wi led the guideline development process and Dr Nathalie Broutet co-led the process under the supervision of Dr James Kiarie and leadership of Dr Ian Askew. Charifa Zemouri provided support during the guideline development process.

FUNDING

The preparation and printing of the guidelines were funded exclusively by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). No external source of funding was solicited or utilized.

CONTRIBUTORS TO WHO GUIDELINE ON SYPHILIS SCREENING AND TREATMENT FOR PREGNANT WOMEN

STI Guideline Development Group (GDG):

Chairpersons: Judith Wasserheit, Holger Schünemann and Patricia Garcia.

Members: Yaw (Sax) Adu-Sarkodie, Andrew Amato, Gail Bolan, John Changalucha, Xiang-Sheng Chen, Harrel Chesson, Craig Cohen, Francisco Garcia, Suzanne Garland, Sarah Hawkes, Mary Higgins, King Holmes, Jeffrey Klausner, David Lewis, Nicola Low, David Mabey, Angelica Espinosa Miranda, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Keith Radcliffe, Ulugbek Sabirov, Judith Stephenson, Richard Steen, Magnus Unemo, Bea Vuylsteke, Anna Wald, Thomas Wong and Kimberly A. Workowski.

STI GDG working group for syphilis: Gail Bolan, John Changalucha, Xiang-Sheng Chen, Patricia Garcia, Suzanne Garland, Jeffrey Klausner, David Mabey, Saiqa Mullick, Joel Palefsky, Ulugbek Sabirov, Richard Steen.

STI External Review Group: Laith Abu-Raddad, Chris Akolo, Adele Schwartz Benzaken, Mircea Betiu, Anupong Chitwarakorn, Carolyn Deal, Margaret Gale-Rowe, William M. Geisler, Mary Kamb, Amina El Kettani, Mizan Kiros, Ahmed Latif, Philippe Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, Pablo Sanchez, Khantanouvieng Sayabounthavong and Aman Kumar Singh.

WHO Steering Committee:

WHO regional offices: Massimo Ghidinelli, Hamida Khattabi, Lali Khotenashvili, Ornella Lincetto, Ying-Ru Lo, Frank Lulu and Razia Pendse.

WHO headquarters: Moazzam Ali, Avni Amin, Rachel Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, Mario Festin, Mary Lyn Gaffield, Antonio Gerbase, Sami Gottlieb, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, Igor Toskin and Marco Vitoria.

WHO STI Secretariat: Ian Askew, Teodora Elvira Wi (lead, development of the guidelines), Nathalie Broutet (co-lead, development of the guidelines), James Kiarie and Charifa Zemouri.

Systematic Review Team: Nancy Santesso (lead), Angela Barbara, Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, Kristie Poole, John Riva, Nicole Schwab, Matthew Ventresca, Yuan Zhang and Andrew Zikic (members).

Methodologist: Nancy Santesso.

ABBREVIATIONS AND ACRONYMS

AIDS	acquired immune deficiency syndrome
AMR	antimicrobial resistance
CI	confidence interval
DOI	declaration of interests
FTA-ABS	fluorescent treponemal antibody absorbed
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GUD	genital ulcer disease
HIV	human immunodeficiency virus
HPV	human papillomavirus
HSV	herpes simplex virus
HSV-2	herpes simplex virus type 2
MSH	Management Sciences for Health
MSM	men who have sex with men
PICO	population, intervention, comparator, outcome
PMTCT	prevention of mother-to-child transmission
RPR	rapid plasma reagin
STI	sexually transmitted infection

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26626

